From the Journals
United States is on the high side for all four subtypes of the disease.
ATLANTA – The findings suggest that results from gene expression profiling could help identify resistant patients.
ATLANTA – The phase 1/2 trial evaluated combined G-CSF, cladribine, high-dose cytarabine, and mitoxantrone in adults with relapsed/refractory AML...
News from the FDA/CDC
The FDA is expected to make a decision in August 2018.
ATLANTA – The 7-year findings could lead to a new strategy for the treatment of high-risk patients with APL.
SAN FRANCISCO – Immune-enriched AML might be amenable to immunotherapy that is tailored to the bone marrow tumor microenvironment.
ATLANTA – A selective mIDH2 inhibitor shows promise as monotherapy, and in combination with azacitidine, in certain AML patients.
MRD-guided azacitidine therapy reduces hematological relapse in patients with MDS or AML at high risk for relapse, according to RELAZA2 trial...
ATLANTA – A novel JAK1 inhibitor shows encouraging activity, particularly with azacitidine, in certain patients with advanced myeloid malignancies...
The expanded indication allows for first-line treatment for adults with newly diagnosed low-risk acute promyelocytic leukemia.